

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

210933Orig1s000

OFFICER/EMPLOYEE LIST

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: October 28, 2020

TO: Administrative file for NDA 210933

FROM: Michael Puglisi, Senior Regulatory Project Manager
Division of Regulatory Operations for Specialty Medicine, Office of Regulatory Operations

SUBJECT: Officer/Employee List for NDA 210933

APPLICATION/DRUG: NDA 210933, EYSUVIS, loteprednol etabonate ophthalmic suspension, 0.25%

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Boyd, William
Chambers, Wiley
Jackson, Kelly
Griffiths, LaShawn
McDougal, Andrew
Fashina, Oyinlola
Townsend, Otto
Somani, Amit
Obrzut, Daniel
Zhang, Chunchun
Ayalew, Kassa
Williams, Marcia Britt
Deng, Yunfan